Advertisement
AXON vs IONS
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON), a leader in public safety technology, has delivered strong year-to-date gains of approximately 29%, outpacing Ionis Pharmaceuticals (IONS) at 7%.
- AXON benefits from recurring software revenue and hardware sales in a growing public safety sector, while IONS relies on biotech pipeline advancements amid clinical risks.
- Recent market activity shows AXON experiencing a share price pullback despite robust growth metrics, contrasting IONS' steady performance driven by clinical data releases.
- AXON commands a larger market cap of $32 billion versus IONS' $12 billion, reflecting differing scales in industrials/tech and biotechnology sectors.
- Analyst sentiment remains positive for both, with AXON highlighted for growth potential and IONS for upcoming catalysts.
Introduction
This stock comparison examines AXON and IONS, representing distinct sectors: public safety technology and biotechnology. Traders seeking sector diversification or investors evaluating growth versus innovation may find value here. With AXON showcasing resilient demand in law enforcement tools and IONS advancing RNA-targeted therapies, the analysis highlights relative performance, sentiment shifts, and market positioning in recent weeks. This objective review aids informed decision-making amid varying risk profiles and economic conditions.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) develops public safety solutions, including TASER conducted energy devices, body cameras, and cloud-based evidence management software like Axon Evidence. The company operates in Software & Services and Connected Devices segments, serving governments and enterprises globally. In recent market activity, AXON has experienced a share price pullback from its 52-week high near $886, trading around $400 with a market cap over $32 billion. Despite this, revenue grew 33% over the past year, fueled by recurring SaaS subscriptions and hardware demand, bolstering sentiment. Analysts cite strong growth metrics and an upcoming Q1 2026 earnings release as key influences, maintaining buy ratings amid broader industrial strength.
IONS Overview and Recent Performance
Ionis Pharmaceuticals, Inc. (IONS) is a biotechnology firm specializing in RNA-targeted medicines, with approved products like TRYNGOLZA for triglyceride reduction and WAINUA for hereditary amyloidosis. Its pipeline includes Phase 3 candidates such as olezarsen and zilganersen for metabolic and neurological disorders. Recently, IONS shares have traded near $73 within a 52-week range of $29 to $87, with a $12 billion market cap. Performance reflects pipeline momentum, including new data on zilganersen for Alexander disease and Q4 2025 earnings, supporting modest YTD gains. Partnerships with Biogen and GSK enhance credibility, though biotech volatility tempers sentiment amid clinical developments.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots selected from over 350, curated by AI analysis for suitability in current market conditions across key industries. These bots employ diverse strategies like trend trading, multi-agent systems, and risk-managed corridors (take-profit/stop-loss), with timeframes from 5 minutes to 55 days. Performance highlights include annualized returns of 15% to 168%, win rates up to 88%, profit factors exceeding 11, and profit-to-drawdown ratios over 21. Examples feature semiconductor-focused bots trading tickers like SOXL (+94% return, 68% win rate) and NVDA/AVGO (+70% return), alongside penny stock and leveraged ETF strategies. Explore these bots to align with your trading style and market outlook.
Head-to-Head Comparison
AXON and IONS diverge sharply in business models: AXON generates stable SaaS recurring revenue (60% gross margins) from public safety tech, contrasting IONS' milestone-driven biotech model reliant on partnerships and approvals. Growth drivers for AXON include expanding drone and AI evidence tools amid rising law enforcement budgets, while IONS hinges on Phase 3 readouts like olezarsen for cardiovascular risk. Recent momentum favors AXON's year-to-date edge, though IONS shows resilience post-earnings. Risk factors highlight AXON's elevated valuation after pullbacks versus IONS' binary clinical outcomes. Sector exposure pits stable industrials against volatile healthcare, with both enjoying positive market sentiment.
Tickeron AI Verdict
Tickeron’s AI currently favors AXON over IONS, citing superior trend consistency, higher YTD returns, and reliable growth in public safety demand versus biotech uncertainties. While IONS offers high-upside catalysts, AXON's relative stability and positioning suggest stronger near-term probability in recent market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and IONS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 5 bearish.
- IONS’s TA Score: 5 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -0.54% price change this week, while IONS (@Biotechnology) price change was +3.97% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.55%. For the same industry, the average monthly price growth was +3.80%, and the average quarterly price growth was +13.63%.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
IONS is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Aerospace & Defense (-3.55% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+5.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | IONS | AXON / IONS | |
| Capitalization | 34.9B | 12.6B | 277% |
| EBITDA | 320M | -217.15M | -147% |
| Gain YTD | -23.751 | -3.944 | 602% |
| P/E Ratio | 165.33 | N/A | - |
| Revenue | 2.98B | 1.06B | 282% |
| Total Cash | 737M | 1.92B | 38% |
| Total Debt | 1.83B | 2.04B | 90% |
AXON | IONS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | 34 | |
SMR RATING 1..100 | 81 | 99 | |
PRICE GROWTH RATING 1..100 | 63 | 44 | |
P/E GROWTH RATING 1..100 | 63 | 62 | |
SEASONALITY SCORE 1..100 | 50 | 1 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (75) in the Biotechnology industry is in the same range as IONS (100). This means that AXON’s stock grew similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (34) in the Biotechnology industry is in the same range as AXON (66). This means that IONS’s stock grew similarly to AXON’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as IONS (99). This means that AXON’s stock grew similarly to IONS’s over the last 12 months.
IONS's Price Growth Rating (44) in the Biotechnology industry is in the same range as AXON (63). This means that IONS’s stock grew similarly to AXON’s over the last 12 months.
IONS's P/E Growth Rating (62) in the Biotechnology industry is in the same range as AXON (63). This means that IONS’s stock grew similarly to AXON’s over the last 12 months.
| AXON | IONS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 64% | N/A |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 74% |
| Advances ODDS (%) | 22 days ago 74% | 1 day ago 66% |
| Declines ODDS (%) | 12 days ago 69% | 16 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 72% | N/A |
Advertisement
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been loosely correlated with CYTK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | +0.13% | ||
| CYTK - IONS | 66% Loosely correlated | +1.06% | ||
| MLYS - IONS | 64% Loosely correlated | +0.91% | ||
| ARWR - IONS | 47% Loosely correlated | -2.60% | ||
| MNKD - IONS | 47% Loosely correlated | +0.77% | ||
| AXON - IONS | 43% Loosely correlated | +5.61% | ||
More | ||||